Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition
Executive Summary
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment
You may also be interested in...
Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.
Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.
Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
Merck KGaA has committed up-front payments and research funding of up to $10 million to Archemix to collaborate on the development and commercialization of first-in-class aptamer-based drugs to treat cancer